Clinical Trials Directory

Trials / Completed

CompletedNCT01177904

Early Progesterone Cessation After in Vitro Fertilization

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
200 (actual)
Sponsor
IVI Madrid · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

There seems to be a general consensus on the supplementation of progesterone (P4) for luteal phase support (LPS) to all women after in vitro fertilization (IVF) treatment. However, there is no agreement about the precise duration of LPS.

Detailed description

The objective of the study is to investigate the effect of early cessation of progesterone for LPS after IVF treatment on the pregnancy outcome, with special interest in determining the miscarriage rate and episodes of bleeding between the date of the first ultrasound (US) and up to 12 weeks of gestation. Patients start to receive 200 mg twice a day of P4 on the day after oocyte retrieval. All patients which show a gestational sac in their uterus in the first US are included in this study and randomized. Inclusion criteria: 1. Patients who underwent ovarian stimulation using GnRH analogues, 2. Fresh embryo transfer, 3. LPS by vaginal micronized P4, 4. Clinical pregnancy demonstrated by US and 5. Informed consent signed. Exclusion criteria: Patients who had bleeding episodes before their first US because they are likely to continue P4 therapy without medical indication.

Conditions

Interventions

TypeNameDescription
OTHERCease progsterone at 5Cease administration of progsterone at first US at 5 weeks
OTHERcontrol group: progesterone 8Control group: progesterone until 8 weeks of pregnancy

Timeline

Start date
2009-01-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2010-08-09
Last updated
2024-04-08
Results posted
2024-04-08

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT01177904. Inclusion in this directory is not an endorsement.